Showing results (1-10 of 51) with videos related to

Sort By:
Pageof 6
Biophysical Journal|September 30, 2004
Force generation by cytoskeletal filament end-tracking proteinsRichard B Dickinson, Luzelena Caro, Daniel L Purich
Clinical and Translational Science|June 14, 2021
Immune-viral dynamics modeling for SARS-CoV-2 drug developmentYoufang Cao, Wei Gao, Luzelena Caro, et al.
International Journal of Antimicrobial Agents|March 30, 2018
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infectionAlan J Xiao, Jennifer A Huntington, Jianmin Long, et al.
Infectious Diseases and Therapy|December 26, 2016
PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal DiseaseAlan J Xiao, Luzelena Caro, Myra W Popejoy, et al.
European Journal of Drug Metabolism and Pharmacokinetics|May 8, 2026
Pharmacokinetics, Safety, and Tolerability of Obeldesivir in Healthy Japanese and White ParticipantsChi-Chi Peng, Eric Salgado, Jessica Corpus, et al.
Clinical Pharmacology in Drug Development|March 9, 2018
Safety, Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults: A Randomized, Placebo-Controlled, Multiple-Dose StudyBrian Yu, Adedayo Adedoyin, Ellie Hershberger, et al.
Antimicrobial Agents and Chemotherapy|April 10, 2019
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal InfectionsKajal B Larson, Yogesh T Patel, Susan Willavize, et al.
Journal of Clinical Pharmacology|January 7, 2011
Pharmacokinetics of oral dexamethasone and midazolam when administered with single-dose intravenous 150 mg fosaprepitant in healthy adult subjectsThomas C Marbury, Phung L Ngo, Craig R Shadle, et al.
Clinical and Translational Science|February 13, 2025
Pharmacokinetics of SARS-CoV-2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic ImpairmentSean Regan, Rita Humeniuk, Luzelena Caro, et al.
Journal of Clinical Pharmacology|January 13, 2018
Pharmacokinetic Interactions Between Elbasvir/Grazoprevir and Immunosuppressant Drugs in Healthy VolunteersHwa-Ping Feng, Luzelena Caro, Christine M Fandozzi, et al.
Pageof 6